In Brief: Ephedra defended
This article was originally published in The Tan Sheet
Executive Summary
Ephedra defended: "Recent attacks on ephedra...Are they motivated by medical science or political hype?" a full-page ad in the Sept. 27 issue of USA Today asks. The ad criticizes FDA and the Texas Health Department for their actions regarding the herb, stating that they "purposefully ignore" the "wide body" of scientific literature and "extensive" studies supporting ephedra's safety. The ad was paid for by the "Ad Hoc Committee on the Safety of Ma Huang." The committee's membership is not disclosed in the ad. The committee spokesperson is Bill Appler, a Washington, D.C.-based consultant. The ad was run in spite of opposition from industry groups including the National Nutritional Foods Association...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning